多西紫杉醇治疗可切除淋巴结阳性乳腺癌30例疗效与安全性观察

Clinical Efficacy and Safety of Docetaxel for Treating Resectable Lymph Node Positive Breast Cancer in 30 Cases

目的探讨多西紫杉醇治疗可切除淋巴结阳性乳腺癌的临床疗效与安全性。方法选择医院肿瘤科2015年收治的60例行乳腺癌改良根治术后的腋窝淋巴结阳性患者,采用平行随机抽样法分为对照组与观察组,各30例。对照组给予表柔比星联合氟尿嘧啶及环磷酰胺(FEC)方案治疗,观察组给予含多西紫杉醇的化学治疗(TEC)方案治疗,对比两组的近期疗效及毒副反应情况。结果观察组总有效率为46.67%,疾病控制率为83.33%,明显高于对照组的16.67%和66.67%,差异均有统计学意义(P<0.05);观察组不良反应(外周神经反应、骨髓毒性反应及消化系统反应)的发生率均明显低于对照组(P<0.05)。结论多西紫杉醇在可切除淋巴结阳性乳腺癌治疗中的临床疗效确切,毒副反应少,可作为该病的首选化学治疗药物。

Objective To investigate the clinical efficacy and safety of docetaxel in treating resectable lymph node positive breast cancer.Methods Totally 60 axillary lymph node positive patients underwent modified radical mastectomy in our hospital in 2015 were divided into the control group and the observation group according to parallel random sampling method,30 cases in each group.The control group was treated with epirubicin combined with fluorouracil and cyclophosphamide（FEC）,and the observation group was treated with chemotherapy with docetaxel（TEC）.The recent curative effects and the toxicity of two groups were compared.Results The total effective rate and the disease control rate of the observation group were 46.67%,83.33%,respectively,which were significantly higher than 16.67% and 66.67% of the control group（P 〈 0.05）.The incidence rate of peripheral nerve reaction,bone marrow toxicity and digestive system reaction in the observation group were significantly lower than those in the control group（P 〈 0.05）.Conclusion Docetaxel in the treatment of resectable lymph node positive breast cancer has good effect and less toxicity,it can be used as the preferred drug for the disease in clinic.